Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents

Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents

Abstract Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of a deterioration in heart failure (HF) and mortality in patients with a broad range of cardiovascular risks. Recent guidelines recommend considering the use of SGLT2 inhibitors in patients with type 2 diabetes (T...

Full description

Bibliographic Details
Main Authors: Atsushi Tanaka, Shigeru Toyoda, Takumi Imai, Kazuki Shiina, Hirofumi Tomiyama, Yasushi Matsuzawa, Takahiro Okumura, Yumiko Kanzaki, Katsuya Onishi, Arihiro Kiyosue, Masami Nishino, Yasushi Sakata, Koichi Node, the CANDLE trial investigators
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Cardiovascular Diabetology
Subjects:
Type 2 diabetes
Chronic heart failure
Sodium–glucose cotransporter 2 inhibitor
Metformin
Dipeptidyl peptidase-4 inhibitor
Online Access:https://doi.org/10.1186/s12933-021-01369-5

Internet

https://doi.org/10.1186/s12933-021-01369-5

Similar Items